Sector News

Medtronic-Covidien to shed 150 jobs at Dublin centre

November 5, 2015
Life sciences

The medical device company Medtronic-Covidien is to shed 150 jobs at its contact centre in Dublin, according to the Communications Workers Union (CWU).
At a meeting with senior management on Monday, staff were told the jobs would be relocated to Poland next June. The contact centre offers support services in a number of languages to European clients.

The CWU has criticised the US firm for refusing to engage with it on the ground at the Cherrywood facility.

“Unfortunately the shocking news was just delivered yesterday and they [staff] are just coming to terms with it,” CWU head of organising Ian McArdle told The Irish Times.

“Quite understandably the staff are in a state of shock. They would have felt that their jobs were secure. . .”

The company could not be reached for comment last night. Mr McArdle said he expected further details to emerge at a meeting between union and staff tonight and appealed to the company to engage.

Last January, Medtronic became the largest company based in Ireland when it began trading on the New York Stock Exchange.

Following its $49.9 billion acquisition of Dublin-domiciled surgical supplies group Covidien, the Minneapolis-based business moved its corporate headquarters to Ireland.

Source: The Irish Times

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach